Literature DB >> 31013262

The Fragility of Statistically Significant Findings in Pediatric Critical Care Randomized Controlled Trials.

Travis J Matics1, Nadia Khan1, Priti Jani1, Jason M Kane1,2.   

Abstract

OBJECTIVES: The Fragility Index measures the number of events on which the statistical significance of a result depends and has been suggested as an adjunct statistical assessment for interpretation of trial results. This study aimed to assess the robustness of statistically significant results from pediatric critical care randomized controlled trials with dichotomous outcomes. DATA SOURCES: A previously published scoping review of pediatric critical care randomized controlled trials (www.PICUtrials.net). STUDY SELECTION: A total of 342 trials were screened for inclusion. After applying inclusion/exclusion criteria, 43 fulfilled eligibility criteria and were included in the analysis. DATA EXTRACTION: Calculation of Fragility Index for trials reporting a statistically significant dichotomous outcome, and analysis of the relationship between trial characteristics and Fragility Index. DATA SYNTHESIS: The median Fragility Index was 2 (interquartile range, 1-6). The median sample size was 98 (interquartile range, 50-148) and sample size demonstrated a strong correlation with the Fragility Index (r = 0.729; n = 43; p < 0.001). The median number of outcome events was 8 (interquartile range, 4-15) and the total number of outcome events also showed a strong correlation with the Fragility Index (r = 0.728; n = 43; p < 0.001).
CONCLUSIONS: Results from pediatric critical care randomized controlled trials with dichotomous outcomes reporting statistically significant findings often hinge on a small number of outcome events. Clinicians should exercise caution when interpreting results of trials with a low Fragility Index.

Mesh:

Year:  2019        PMID: 31013262     DOI: 10.1097/PCC.0000000000001922

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  8 in total

Review 1.  Statistical Fragility of Single-Row Versus Double-Row Anchoring for Rotator Cuff Repair: A Systematic Review of Comparative Studies.

Authors:  Nathan P Fackler; Cooper B Ehlers; Kylie T Callan; Arya Amirhekmat; Eric J Smith; Robert L Parisien; Dean Wang
Journal:  Orthop J Sports Med       Date:  2022-05-10

Review 2.  The Statistical Fragility of Single-Bundle vs Double-Bundle Autografts for ACL Reconstruction: A Systematic Review of Comparative Studies.

Authors:  Cooper B Ehlers; Andrew J Curley; Nathan P Fackler; Arjun Minhas; Ariel N Rodriguez; Kory Pasko; Edward S Chang
Journal:  Orthop J Sports Med       Date:  2021-12-20

3.  Reverse Bayesian Implications of p-Values Reported in Critical Care Randomized Trials.

Authors:  Sarah Nostedt; Ari R Joffe
Journal:  J Intensive Care Med       Date:  2021-11-29       Impact factor: 2.889

4.  Paediatric surgical trials, their fragility index, and why to avoid using it to evaluate results.

Authors:  Arne Schröder; Oliver J Muensterer; Christina Oetzmann von Sochaczewski
Journal:  Pediatr Surg Int       Date:  2022-05-07       Impact factor: 2.003

5.  Fragility of statistically significant findings from randomized clinical trials of surgical treatment of humeral shaft fractures: A systematic review.

Authors:  Stephen Craig Morris; Anirudh K Gowd; Avinesh Agarwalla; Wesley P Phipatanakul; Nirav H Amin; Joseph N Liu
Journal:  World J Orthop       Date:  2022-09-18

6.  How Robust are the Evidences that Formulate Surviving Sepsis Guidelines? An Analysis of Fragility and Reverse Fragility of Randomized Controlled Trials that were Referred in these Guidelines.

Authors:  Nang S Choupoo; Saurabh K Das; Priyam Saikia; Samarjit Dey; Sumit Ray
Journal:  Indian J Crit Care Med       Date:  2021-07

7.  Fake news and fake research: Why meta-research matters more than ever.

Authors:  Richard G McGee; Amanda C Dawson
Journal:  J Paediatr Child Health       Date:  2020-10-21       Impact factor: 1.954

8.  Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.

Authors:  Brooke E Wilson; Alexandra Desnoyers; Michelle B Nadler; Ariadna Tibau; Eitan Amir
Journal:  Cancer Med       Date:  2021-07-28       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.